10064- ML-2 CLINICAL CHARACTERISTICS OF NON-COMPLETE RESPONDERS TO MTX-BASED INDUCTION THERAPY IN PATIENTS WITH PRIMARY CNS LYMPHOMA
Motoo Nagane, Nobuyoshi Sasaki, Kuniaki Saito, Keiichi Kobayashi, Kazuha Kugasawa · 2024
Read 10064- ML-2 CLINICAL CHARACTERISTICS OF NON-COMPLETE RESPONDERS TO MTX-BASED INDUCTION THERAPY IN PATIENTS WITH PRIMARY CNS LYMPHOMA by Motoo Nagane, Nobuyoshi Sasaki, Kuniaki Saito, Keiichi Kobayashi, Kazuha Kugasawa (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11605634.txt.
Description
Motoo Nagane and four co-authors report a 2024 conference study of primary lymphoma of the central nervous system. Standard first treatment uses high dose methotrexate based therapy, often a regimen called R-MPV, and most patients respond fully. Those who do not respond face a worse outlook, and the signs of poor response are unclear.
The team reviewed 107 patients treated at one center between 2011 and 2023. About four in five reached a full response after treatment, while about one in five did not. Dose cuts or stops for some drugs tracked with shorter time before the disease grew again. The authors use these patterns to describe which patients may need closer watch.
Catalog record
| CREATOR | Motoo Nagane, Nobuyoshi Sasaki, Kuniaki Saito, Keiichi Kobayashi, Kazuha Kugasawa |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |